Document:

Exhibit 10.7  

Nace Resources. Inc.

69 MacArthur Loop

Highland Park, IL 60035  

August 29,
2002 

Craig
Dees, Ph.D.

Chief Executive Officer

Provectus Pharmaceuticals, Inc.

7327 Oak Ridge Highway, Suite B

Knoxville, TN 37931 

Dear
Craig: 

        This
is to confirm the engagement of NRI, Inc. ("NRI") by Provectus Pharmaceuticals, Inc. (the "Company") to render certain investment banking services in connection with a
contemplated private placement or other sale by the Company (the "Contemplated Private Placement") to one or more potential investors of securities of the Company, which could include, without
limitation, debt or equity securities of the Company; options, warrants or rights to acquire debt or equity securities convertible into or exchangeable for debt or equity securities of the Company
("Senior Securities"). 

        1.    Services to be Rendered.    NRI will perform such of the following services in connection with the Contemplated
Private Placement as the Company may reasonably request: 

	a.
	NRI
will familiarize itself to the extent it deems appropriate with the business, operations, financial condition and prospects of the Company;

	b.
	NRI
will assist the Company in revising as necessary and distributing a Confidential Offering Memorandum of the Company relating to the Contemplated Private Placement (the
"Confidential Memorandum");

	c.
	NRI
will assist the company in the process of identifying a number of potential accredited investors which might have an interest in receiving the Confidential Memorandum and
evaluating participation in the Contemplated Private Placement;

	d.
	Upon
authorization from the Company, NRI will contact one or more of such Contemplated investors;

	e.
	NRI
will assist the Company and its Board of Directors in evaluating proposals received from any such potential investors;

	f.
	NRI
will participate with the Company and its counsel in negotiations relating to the Contemplated Private Placement; and

	g.
	NRI
will participate in meetings of the Board of Directors of the Company (such participation to be in person or by telephone, as appropriate) at which the Contemplated Private
Placement is to be considered and, as appropriate, will report to the Board of Directors with respect thereon. 

        In
connection with NRI's activities on the Company's behalf, the Company agrees to cooperate with NRI and will furnish to, or cause to be furnished to, NRI all information and data
concerning the Company (the "Information") which NRI reasonably deems appropriate for purposes of the Confidential Memorandum or otherwise and will provide NRI with access to the Company's officers,
directors, employees and advisors. The Company represents and warrants that all Information made available to NRI by the Company with respect to a Contemplated Private Placement or otherwise included
or incorporated by reference in the Confidential Memorandum will be complete and correct and that any projections, forecasts or other Information provided by the Company to NRI will have 

 

been prepared in good faith and will be based upon reasonable assumptions. The Company agrees to promptly notify NRI if the Company believes that any Information previously provided to NRI has become
materially misleading. The Company acknowledges and agrees that, in rendering its services hereunder, NRI will be using and relying on the Information (and information available from public sources
and other sources deemed reliable by NRI) without independent verification thereof or independent appraisal or evaluation of the Company, or any party to the transaction. NRI does not assume
responsibility for the accuracy or completeness of the Information, the Confidential Memorandum or any other information regarding the Company. If all or any portion of the business of the Company is
engaged in through subsidiaries or other affiliates, the references in this paragraph to the Company will, when appropriate, be deemed also to include such subsidiaries or other affiliates. 

        It
is further understood that any advice rendered by NRI during the course of participating in negotiations and meetings of the Board of Directors of the Company, as well as any written
materials provided by NRI, are intended solely for the benefit and confidential use of the Board of Directors and will not be reproduced, summarized, described or referred to or given to any other
person for any purpose without NRI's prior written consent. 

        The
Company represents to NRI that the Company has not engaged in any other offering of securities and has taken all actions necessary that would cause the Contemplated Private Placement
to qualify for an applicable exemption from registration under the Securities Act of 1933, as amended. 

        2.    Fees.    In the event that the Contemplated Private Placement is consummated with an investor introduced to the
Company by NRI, the Company will pay or cause to be paid to NRI a fee (the "Placement Fee") as a result of such consummation. The Placement Fee will consist of the following: (a) cash equal to
five percent (5%) of the Transaction Consideration (as defined below); and (b) warrants for the purchase of the Company's common stock at an exercise price equal to the per share price of
common stock paid to the Company in connection with the Private Placement or the per share price at which any Senior Security issued in connection with the Private Placement is convertible into shares
of the Company's common stock. The total number of shares underlying the Transaction Consideration if any, and five percent (5%) of the number of shares of common stock into which any Senior Security
issued in connection with the Private Placement is convertible; provided, however, that the total number of shares underlying the warrants shall in no
event exceed 50,000 per $1,000,000 of Transaction Consideration. The warrants shall have a term of five years. 

        For
purposes of this letter agreement, the term "Transaction Consideration" will mean the total amount of cash and the fair market value of the other property paid, payable or
contributed directly or
indirectly to the Company, any of its security holders or any of its shareholders or executive officers in connection with the Contemplated Private Placement. 

        The
Placement Fee will be payable in full upon the closing of the Contemplated Private Placement; provided, however, that if the
Transaction Consideration includes consideration the receipt of which is contingent upon the passage of time or the occurrence of some future event or circumstance ("Contingent Value"), the portion of
the Placement Fee attributable to such Contingent Value will be paid to NRI at the earlier of (x) the date on which payment of such Contingent Value is due of (y) the time that such
Contingent Value can be determined or reasonably estimated. 

        If
any portion of the Transaction Consideration is received in the form of securities for which a public trading market existed prior to consummation of the Contemplated Private
Placement, the value of such securities, for purposes of calculating the Transaction Consideration, will be based on the 30-day trading average ending on the last trading day prior to the
consummation of the Contemplated Private Placement. If such securities do not have an existing public trading market, the value of the securities will be the mutually agreed upon fair market value
thereof. 

2

 

        3.    Expenses.    Subject to a cap of $25,000, the Company will at the closing of the transaction reimburse NRI for
all out-of-pocket expenses (including fees and expenses of its counsel and any other independent experts retained by NRI) reasonably incurred by it in connection with its
engagement hereunder. Any reimbursable expense in excess of $1,000 requires the prior written approval of an unauthorized officer of the Company. 

        4.    Indemnification, Contribution and Limit on Liability.    The Company agrees that it will indemnify and hold
harmless NRI and its affiliates, and its and their respective directors, officers, employees, agents and controlling persons (NRI and each such person being an "Indemnified Party") from and against
all losses, claims, damages and liabilities, joint or several, as incurred, to which such Indemnified Party may become subject under any applicable United States federal or state law, or otherwise,
and related to or arising out of (i) any untrue statement or alleged untrue statement of a material fact contained in any information (whether oral or written) or documents, including without
limitation the Confidential Memorandum, Information and public information, furnished or made available by the Company, directly, through NRI or otherwise, to any offeree of any of the Company's
securities or any of their representatives or the omission or the alleged omission to state therein a material fact necessary in order to make the statements therein not misleading, in the light of
the circumstances under which they were made, or (ii) any transaction contemplated by this letter agreement or the engagement of NRI pursuant to, and the performance by NRI of the services
contemplated by, this letter agreement; provided, however, that the Company will not be liable under clauses (i) and (ii) hereof to the extent that any loss, claim, damage or liability
is found in a final judgment by a court to have resulted from NRI's misrepresentation of a material fact contained in any information (whether oral or written) or documents prepared in whole or in
part by NRI's bad faith, willful misconduct or gross negligence in performing the services described above. The Company also agrees to reimburse any Indemnified Party for all expenses (including
counsel fees and expenses) as they are incurred in connection with the
investigation of, preparation for or defense of any pending or threatened claim or any action or proceeding arising therefrom, whether or not such Indemnified Party is a party and whether or not such
claim, action or proceeding is initiated or brought by or on behalf of the Company. The Company also agrees that no Indemnified Party shall have any liability (whether direct or indirect, in contract
or tort or otherwise) to the Company or its equity holders or creditors related to or arising out of the engagement of NRI pursuant to, or the performance by NRI of the services contemplated by, this
Agreement except to the extent that any loss, claim, damage or liability is found in a final judgment by a court to have resulted from NRI's bad faith, willful misconduct or gross negligence. 

        If
the indemnification provided for in this letter agreement is for any reason held unenforceable, the Company agrees to contribute to the losses, claims, damages and liabilities, as
incurred, for which such indemnification is held unenforceable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and NRI, on the other hand, of the
Contemplated Private Placement (whether or not the Contemplated Private Placement is consummated), provided, however, that no person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Company agrees that for the purposes of this
paragraph the relative benefits to the Company and NRI of the Contemplated Private Placement as contemplated shall be deemed to be in the same proportion that the total value of securities sold or
contemplated to be sold by the Company as a result of or in connection with the Proposed Private Placement bears to the Fee paid or to be paid to NRI under this letter agreement; provided, however,
that, to the extent permitted by applicable law, in no event shall the Indemnified Parties be required to contribute an aggregate amount in excess of the aggregate Fee actually paid to NRI under this
Agreement. 

        5.    Notices, Defense and Settlement of Claim, Action or Proceedings.    Promptly after receipt by an Indemnified
Party of notice of any claim or the commencement of any action or proceeding with 

3

 

respect to which an Indemnified Party may be entitled to indemnity hereunder, the Indemnified Parties will notify the Company in writing of such claim or of the commencement of such action or
proceeding, and the Company will assume the defense of such action or proceeding and will employ counsel satisfactory to the Indemnified Parties and will pay the fees and expenses of such counsel, as
incurred. Notwithstanding the preceding sentence, any Indemnified Party will be entitled to employ counsel separate from counsel for the Company and from any other party in such action if such
Indemnified Party has been advised by counsel that a conflict of interest exists which makes representation by counsel chosen by the Company not advisable or if such Indemnified Party has been advised
by counsel that Company's assumption of the defense does not adequately represent its interest. In such event, the Company will pay the fees and disbursements of one such separate counsel for all
Indemnified Parties. 

        The
Company agrees that, without NRI's prior written consent, it will not settle, compromise or consent to the entry of any judgment in any pending or threatened claim, action or
proceeding in respect of which indemnification could be sought under the indemnification provision of this Agreement (whether or not NRI or any other Indemnified Party is an actual or potential party
to such claim, action or proceeding), unless such settlement, compromise and consent includes an unconditional release of each Indemnified Party from all liability arising out of such claim, action or
proceeding. The Company shall not be liable for any settlement, compromise or consent effected without its written consent. 

        In
the event NRI or any Indemnified Party is requested or required to appear as a witness in any action brought by or on behalf of or against the Company or any affiliate or any
participant in a transaction covered hereby in which NRI or such Indemnified Party is not named as a defendant, the Company agrees to reimburse NRI for all expenses incurred by it in connection with
such Indemnified Party's appearing and preparing to appear as a witness, including, without limitation the fees and disbursements of its legal counsel. 

        6.    Termination.    NRI's engagement under may be terminated by either the Company or NRI at any time, with or
without cause, upon written notice to the other party; provided, however, that (a) no such termination will affect NRI's right to expense reimbursement under Section 3, the payment of
any accrued and unpaid fees pursuant to Section 2 or the indemnification contemplated by Section 4 and (b) if the Company, directly or indirectly, consummates the Contemplated
Private Placement within twenty-four months following such termination with any party (i) which NRI has identified, or (ii) in respect to which NRI has rendered advice, or
(iii) with which the Company has directly or indirectly held discussions or furnished information regarding the Company prior to such termination, then NRI will be entitled to the full amount
of the fee contemplated by Section 2. Subject to the provisions of this paragraph, NRI's engagement will terminate six (6) months from the date hereof. 

        7.    Government Law; Jurisdiction; Waiver of Jury Trial.    This letter agreement and the Indemnity Agreement will be
deemed made in Illinois and will be governed by the laws of the State of Illinois. The Company irrevocably submits to the jurisdiction of any court of the State of Illinois or the United States
District Court of the Northern District of the State of Illinois for the purpose of any suit, action or other proceeding arising out of this letter agreement, or any of the agreements or transactions
contemplated hereby, which is brought by or against the Company. Each of the Company (and, to the extent permitted by law, on behalf of the Company's equity holders and creditors) and NRI hereby
knowingly, voluntarily and irrevocably waives any right it may have to a trial by jury in respect of any claim based upon, arising out of or in connection with this letter agreement and the
transactions contemplated hereby (including, without limitation, any Contemplated Private Placement). 

        8.    No Rights in Equityholders, Creditors.    This letter agreement does not create, and will not be construed as
creating, rights enforceable by any person or entity not a party hereto. The Company acknowledges and agrees that (a) NRI will act as an independent contractor and is being retained solely to
assist the Company in its efforts to effect a Contemplated Private Placement and that, NRI is 

4

 

not being retained to advise the Company on, or to express any opinion as to, the wisdom, desirability or prudence of consummating a Contemplated Private Placement, (b) NRI is not and will not
be construed as a fiduciary of the Company or any affiliate thereof and will have no duties or liabilities to the equityholders or creditors of the company, and affiliates of the Company or any other
person by virtue of this letter agreement and the retention of NRI hereunder, all of which duties and liabilities are hereby expressly waived and (c) nothing contained herein shall be construed
to obligate NRI to purchase, as principal, any of the securities offered by the Company in the Contemplated Private Placement. Neither equity holders nor creditors of the Company are intended
beneficiaries hereunder. The Company confirms that it will rely on its own counsel, accountants and other similar expert advisors for legal, accounting, tax and other similar advice. 

        9.    NRI; Other Activities.    It is understood and agreed that NRI or one of its affiliate companies, including Nace
Pharma, LLC, may, from time to time, perform investment banking or other services for the Company and other entities that are or may be the subject of the engagement contemplated by this letter
agreement. This is to confirm that Contemplated investors identified or contacted by NRI could include entities in respect of which NRI or its affiliates may have rendered or may in the future render
services. 

        10.    Other.    This letter agreement may not be modified or amended except in writing executed in counterparts, each
of which will be deemed an original and all of which will constitute one and the same instrument. 

        If
the foregoing correctly sets forth our agreement, please so indicate by signing below and returning an executed copy to us. We look forward to working with you. 

	 	 	Best regards,
	

 	
 	

NACE RESOURCES, INC.
	

 	
 	

By:	
 	

/s/  STUART FUCHS      

	

 	
 	

Name: Stuart Fuchs

Its:     President

	

ACCEPTED AND AGREED AS OF:

THE DATE FIRST ABOVE WRITTEN	
 	

 
	

PROVECTUS PHARMACEUTICALS, INC.	
 	

 
	

By:	
 	

/s/  CRAIG DEES      
 Craig Dees, Ph.D.

Chief Executive Officer	
 	

 

5Exhibit 10.8  

CONFIDENTIALITY, INVENTIONS AND

NON-COMPETITION AGREEMENT  

        This CONFIDENTIALITY, INVENTIONS AND NON-COMPETITION AGREEMENT, dated as of November 26, 2002
(the "Agreement"), is by and between Provectus Pharmaceuticals, Inc., a Nevada corporation, its successors and assigns (the
"Company") and H. Craig Dees ("You" or "Your"). 

RECITALS  

        WHEREAS, pursuant to that certain Convertible Secured Promissory Note and Warrant Purchase Agreement (the
"Purchase Agreement"), dated as of even date herewith, by and between Company, and Gryffindor Capital Partners I, L.L.C. a Delaware limited liability
limited company ("Gryffindor"), Gryffindor is purchasing a convertible secured promissory note in the original principal amount of $1,000,000 and a
warrant to purchase shares of Company's common stock (the "Transaction"). 

        WHEREAS, You are an officer, shareholder and/or optionholder of Company and also currently are an employee of Company or provide services
to Company. 

        WHEREAS, You will receive a substantial economic benefit upon the consummation of the Transaction. 

        WHEREAS, one of the conditions of Gryffindor to consummate the Transaction pursuant to the terms of the Purchase Agreement is that You
enter into this Agreement. 

        NOW, THEREFORE, to induce Gryffindor to consummate the Transaction pursuant to the Purchase Agreement and in consideration of Your
continued employment with Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and You agree as follows: 

        1.    Confidential Information. 

        a.    You
acknowledge that the Confidential Information (as defined below) constitutes a protectible business interest of the Company, and covenant and agree that You will not,
directly or indirectly, disclose, furnish, make available or utilize any Confidential Information other than in the course of performing duties as an employee of the Company. You will abide by Company
policies and rules as may be established from time to time by it for the protection of its Confidential Information. Your obligations under this  Section 1.a. will continue at all times during the
period of Your employment and will survive expiration or termination of this Agreement, and
Your employment with the Company for five (5) years following the end of Your employment with the Company; provided, however, that in the event that an item of Confidential Information
constitutes a trade secret, Your obligations under this Section 1.a. with respect to that particular item of Confidential Information shall
survive for as long as that particular item of Confidential Information remains a trade secret, but in no event less than five (5) years following the end of Your employment with the Company. 

        b.    As
used in this Agreement, the term "Confidential Information" means any and all confidential, proprietary or trade secret
information from any source, whether disclosed, directly or indirectly, verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by
You, applicable to or in any way related to: (i) the present or future business of the Company or any of its Affiliates (as defined below); (ii) the research and development of the
Company or any of its Affiliates; or (iii) the business of any client or vendor of the Company or any of its Affiliates that the Company is required to keep confidential. Such Confidential
Information includes, by way of example and without limitation, the following 

1

 

property or information of the Company and its Affiliates: the Inventions and all trade secrets, processes, formulas, data, program documentation, customer lists, designs, drawings, algorithms,
source code, object code, know-how, improvements, inventions, licenses, techniques, all plans or strategies for marketing, development and pricing, business plans, financial statements,
profit margins and all information concerning existing or potential clients, suppliers or vendors. Confidential Information of the Company also means all similar information disclosed to the Company
by third parties which is subject to confidentiality obligations. The term "Affiliates" means: (iv) all persons or entities controlling,
controlled by or under common control with, the Company; (v) all companies or entities in which the Company owns an equity interest; and (vi) all predecessors, successors and assigns of
the those Affiliates identified in (iv) and (v). 

        2.    Return of Materials. Upon termination of employment with the Company, and regardless of the reason for such termination,
You will leave with, or promptly return to, the Company all documents, records, notebooks, magnetic tapes, disks or other materials, including all copies, in Your possession or
control which contain Confidential Information or any other information concerning the Company, any of its Affiliates or any of its or their products, services or clients, whether prepared by You or
others. 

        3.    No Improper Use of Information of Prior Employers and Others. During Your employment by the Company, You will not
improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom You have an obligation of confidentiality, and You will not bring
onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom You have an obligation of confidentiality unless consented to in
writing by that former employer or person. You will use in the performance of Your duties only information which is generally known and used by persons with training and experience comparable to Your
own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. 

        4.    Inventions as Sole Property of the Company. 

        a.    You
covenant and agree that all Inventions (as defined below) shall be the sole and exclusive property of the Company. 

        b.    As
used in this Agreement, "Inventions" means any and all inventions, developments, trade secrets, processes, formulas,
source and object codes, data, programs, know-how, show-how, discoveries, improvements, works of authorship, concepts, mask works, or ideas, or expressions thereof, whether or
not subject to patents, copyright, trademark, trade secret protection or other intellectual property right protection (in the United States or elsewhere), and whether or not reduced to practice,
conceived or developed by You (i) prior to your employment with Company (including, without limitation, all of Your right, title and interest in and to the technologies and other intellectual
property rights associated with the Therapeutic Business (defined in Separation Agreement) as set forth in Schedule B to the Separation Agreement by and among You and certain other parties,
dated July 29, 2002 (the "Separation Agreement")), (ii) during Your employment with the Company or (iii) within one (1) year
following termination of such employment, which, in the case of (i), (ii) and (iii), relate to or result from the actual or anticipated business, work, research or investigation of the Company
or any of its Affiliates or which are suggested by or result from any task assigned to or performed by You for the Company or any of its Affiliates. 

        c.    You
acknowledge that all original works of authorship which are made by You (solely or jointly) are works made for hire under the United States Copyright Act (17 U.S.C.,
et seq.). 

        d.    You
agree to promptly disclose to the Company all Inventions, all original works of authorship and all work product relating thereto. This disclosure will include
complete and 

2

 

accurate copies of all source code, object code or machine-readable copies, documentation, work notes, flowcharts, diagrams, test data, reports, samples and other tangible evidence or results
(collectively, "Tangible Embodiments") of such Inventions, works of authorship and work product. All Tangible Embodiments of any Invention, work of
authorship or work product related thereto will be deemed to have been assigned to the Company as a result of the act of expressing any Invention or work of authorship therein. 

        e.    You
hereby assign to the Company (together with the right to prosecute or sue for infringements or other violations of the same) the entire worldwide right, title and
interest to any such Inventions or works made for hire, and You agree to perform, during and after employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the
Company's expense, in registering, recording, obtaining, maintaining, defending, enforcing and assigning Inventions or works made for hire in any and all countries. You hereby irrevocably designate
and appoint the Company and its duly authorized officers and agents as Your agents and attorneys-in-fact to act for and on Your behalf and instead of You, to execute and file
any documents and to do all other lawfully permitted acts to further the above purposes with the same legal force and effect as if executed by You; this designation and appointment constitutes an
irrevocable power of attorney and is coupled with an interest. 

        f.      Without
limiting the generality of any other provision of this Section 4, You hereby authorize the Company and each
of its Affiliates (and their respective successors) to make any desired changes to any part of any Invention, to combine it with other materials in any manner desired, and to withhold Your identity in
connection with any distribution or use thereof alone or in combination with other materials. 

        g.    The
obligations of You set forth in this Section 4 (including, without limitation, the assignment obligations) will
continue beyond the termination of Your employment with respect to Inventions conceived or made by You alone or in concert with others during Your employment with the Company and during the one
(1) year thereafter, whether pursuant to this Agreement or otherwise. These obligations will be binding upon You and Your executors, administrators and other representatives. 

        5.    Restrictive Covenants. 

        a.    You
will not, during the term of Your employment with the Company, and for an eighteen (18) month period
immediately thereafter (collectively, the "Restricted Period"), directly or indirectly (whether as an owner, partner, shareholder, agent, officer,
director, employee, independent contractor, consultant, or otherwise) with or through any person or entity, whether or not for monetary benefit, engage in the development of (i) prescription
drugs, medical and other devices (including laser devices) and over-the-counter pharmaceuticals in the fields of dermatology and oncology, and (ii) technologies for the
preparation of human and animal vaccines, diagnosis of infectious diseases and enhanced production of genetically engineered drugs. The Restricted Period shall be extended for a period equal to any
time period that You are in violation of this Section 5. 

        b.    You
will not, during the Restricted Period, directly or indirectly (whether as an owner, partner, shareholder, agent,
officer, director, employee, independent contractor, consultant, or otherwise) with or through any person or entity: 

            i.  employ,
engage or solicit for employment any person who is, or was at any time during the immediately preceding twelve (12) month period, an employee of the
Company or any of its Affiliates, or otherwise seek to adversely influence or alter such person's relationship with the Company or any of its Affiliates; or 

          ii.  solicit
or encourage any person or entity that is, or was, at any time, during the immediately preceding twelve (12) month period a prospective Affiliate of the
Company or a 

3

 

customer or vendor or prospective customer or vendor of the Company or any of its Affiliates, to terminate or otherwise alter his, her or its relationship with the Company or any of its Affiliates;
or 

          iii.  accept
a position with any person or entity that is, or was, at any time during the immediately preceding twelve (12) month period, a customer or vendor or
prospective customer or vendor of the Company or any of its Affiliates. 

        6.    Equitable Remedies. You acknowledge and agree that the agreements and covenants set forth in this Agreement are reasonable
and necessary for the protection of the Company's business interests, that irreparable injury will result to the Company if You breach any of the terms of said covenants, and that in the event of Your
actual or threatened breach of any such covenants, the Company will have no adequate remedy at law. You accordingly agree that, in the event of any actual or threatened breach by You of any of said
covenants, the Company will be entitled to immediate injunctive and other equitable relief, without bond and without the necessity of showing actual monetary damages. Nothing in this  Section 6 will
be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach,
including the recovery of any damages that it is able to prove. 

        7.    Modification and Waiver. This Agreement may not be modified or amended except by an instrument in writing signed by the
parties. No term or condition of this Agreement will be deemed to have been waived, except by written instrument of the party charged with such waiver. No such written waiver will be deemed to be a
continuing waiver unless specifically stated therein, and each such waiver will operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for
the future or as to any act other than that specifically waived. 

        8.    Severability. You acknowledge that the agreements and covenants contained in this Agreement are essential to protect the
Company and its goodwill. Each of the covenants in this Agreement will be construed as independent of any other covenants or other provisions of this Agreement. If any court of competent jurisdiction
at any time deems the Restricted Period unreasonably lengthy or any of the
covenants set forth in this Agreement not fully enforceable, the other provisions of this Agreement will nevertheless stand and to the full extent consistent with law continue in full force and
effect, and it is the intention and desire of the parties that the court treat any provisions of this Agreement which are not fully enforceable as having been modified to the extent deemed necessary
by the court to render them reasonable and enforceable and that the court enforce them to such extent (for example, that the Restricted Period be deemed to be the longest period permissible by law,
but not in excess of the length provided for in Section 5). 

        9.    Notices. Any notice, consent, waiver and other communications required or permitted pursuant to the provisions of this
Agreement must be in writing and will be deemed to have been properly given: (a) when delivered by hand; (b) when sent by telecopier (with acknowledgment of complete transmission),
provided that a copy is mailed by U.S. certified mail, return receipt requested; (c) three (3) days after sent by certified mail, return receipt requested; or (d) one
(1) day after deposit with a nationally recognized overnight delivery service, in each case to the appropriate addresses and telecopier numbers set forth below: 

	If to the Company:	 	Provectus Pharmaceuticals, Inc.

7327 Oak Ridge Highway, Suite A

Knoxville, TN 37931

Attention: Timothy C. Scott, Ph.D., President

Facsimile No. (865) 539-9654
	

If to You:	
 	

                                         
               
	 	 	                                        
                
	 	 	Attn:
                                         
       
	 	 	Telecopy No.: (      )
                        

4

 

Each
party will be entitled to specify a different address for the receipt of subsequent notices by giving written notice thereof to the other party in accordance with this  Section 9. 

        10.  Headings. The headings and other captions in this Agreement are included solely for convenience of reference and will not
control the meaning and interpretation of any provision of this Agreement. 

        11.  Governing Law. This Agreement has been executed in the State of Tennessee, and its validity, interpretation, performance,
and enforcement will be governed by the laws of such state, except with respect to conflicts of laws principles. The parties hereby consent to the exclusive jurisdiction of the
Federal or state courts in Tennessee in any action or claim arising out of, under or in connection with this Agreement, or the relationship between the parties hereto. 

        12.  Binding Effect. This Agreement will be binding upon and inure to the benefit of You, the Company, and their respective
successors and permitted assigns. The Company will be entitled to assign its rights and duties under this Agreement provided that the Company will remain liable to You should such assignee fail to
perform its obligations under this Agreement. 

        13.  No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rule of strict construction will be applied against any person. 

        14.  Records; No Conflicting Obligations. You agree to keep and maintain adequate and current records (in the form of notes,
sketches, drawings and in any other form that may be required by the Company) of all Inventions developed by You and all Inventions made by You during the period of Your employment at the Company,
which records shall be available to and remain the sole property of the Company at all times. You represent that Your performance of all the terms of this Agreement and as an employee of the Company
does not and will not breach any agreement or obligation of any kind made prior to Your employment by the Company, including agreements or obligations You may have with prior employers or entities for
which You have provided services. You have not entered into, and You agree You will not enter into, any agreement or obligation either written or oral in conflict herewith. 

        15.  Employee-at-Will; Notification of New Employer. You agree and understand that You are employed
at-will, and that nothing in this Agreement shall change this at-will status or confer any right with respect to continuation of employment by the Company, nor shall it
interfere in any way with Your right or the Company's right to terminate Your employment at any time, with or without cause. In the event that You leave the employ of the Company for any reason or no
reason, You authorize the Company to provide notice of Your rights and obligations under this Agreement to Your subsequent employer and to any other entity or person to whom You provide services. 

        16.  Incorporation of Recitals. The recitals are hereby incorporated into this Agreement by this reference. 

        17.  Waiver of Jury. The Company and You knowingly and voluntarily waive any and all right to a trial by jury in any action or
proceeding arising out of, under or in connection with this Agreement, or the relationship between the parties hereto. 

5

 

        IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and You have signed this
Agreement, as of the date written below. 

PROVECTUS PHARMACEUTICALS, INC.  

	By:	 	/s/  TIMOTHY C. SCOTT      	 	By:	 	 
	 	 	
	 	 	 	

	

Title:	
 	

President	
 	

Name:	
 	

 
	 	 	
	 	 	 	

	

Date:	
 	

11/26/02	
 	

Date:	
 	

 
	 	 	
	 	 	 	

YOU  

	Signed:	 	/s/  H. CRAIG DEES      
 H. Craig Dees	 	 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]